Department of Pathology and Molecule Medicine
Dawn M. E. Bowdish has not added Biography.
If you are Dawn M. E. Bowdish and would like to personalize this page please email our Author Liaison for assistance.
The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization.
Journal of immunology (Baltimore, Md. : 1950) Jan, 2004 | Pubmed ID: 14707090
The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes.
Journal of immunology (Baltimore, Md. : 1950) Mar, 2004 | Pubmed ID: 15004180
Impact of LL-37 on anti-infective immunity.
Journal of leukocyte biology Apr, 2005 | Pubmed ID: 15569695
A re-evaluation of the role of host defence peptides in mammalian immunity.
Current protein & peptide science Feb, 2005 | Pubmed ID: 15638767
Immunomodulatory activities of small host defense peptides.
Antimicrobial agents and chemotherapy May, 2005 | Pubmed ID: 15855488
Anti-endotoxin properties of cationic host defence peptides and proteins.
Journal of endotoxin research , 2005 | Pubmed ID: 16176660
Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37.
American journal of respiratory cell and molecular biology Apr, 2006 | Pubmed ID: 16340000
Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37.
Journal of immunology (Baltimore, Md. : 1950) Feb, 2006 | Pubmed ID: 16456005
The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system.
Journal of leukocyte biology Sep, 2006 | Pubmed ID: 16793910
IRAK-4 mutation (Q293X): rapid detection and characterization of defective post-transcriptional TLR/IL-1R responses in human myeloid and non-myeloid cells.
Journal of immunology (Baltimore, Md. : 1950) Dec, 2006 | Pubmed ID: 17114497
CD312, the human adhesion-GPCR EMR2, is differentially expressed during differentiation, maturation, and activation of myeloid cells.
Biochemical and biophysical research communications Feb, 2007 | Pubmed ID: 17174274
Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways.
Journal of immunology (Baltimore, Md. : 1950) Dec, 2007 | Pubmed ID: 18025214
Conserved domains of the class A scavenger receptors: evolution and function.
Immunological reviews Jan, 2009 | Pubmed ID: 19120472
MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis.
PLoS pathogens Jun, 2009 | Pubmed ID: 19521507
Host defence peptide LL-37 induces IL-6 expression in human bronchial epithelial cells by activation of the NF-kappaB signaling pathway.
Journal of innate immunity , 2009 | Pubmed ID: 20375583
Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia.
Cell host & microbe Sep, 2010 | Pubmed ID: 20833375
The macrophage.
Methods in molecular biology (Clifton, N.J.) , 2012 | Pubmed ID: 22262440
The evolution of the class A scavenger receptors.
BMC evolutionary biology , 2012 | Pubmed ID: 23181696
MARCO is required for TLR2- and Nod2-mediated responses to Streptococcus pneumoniae and clearance of pneumococcal colonization in the murine nasopharynx.
Journal of immunology (Baltimore, Md. : 1950) Jan, 2013 | Pubmed ID: 23197261
Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.
Journal of leukocyte biology Apr, 2013 | Pubmed ID: 23341539
Immunosenescence and novel vaccination strategies for the elderly.
Frontiers in immunology , 2013 | Pubmed ID: 23825474
HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium.
Journal of immunology (Baltimore, Md. : 1950) Oct, 2013 | Pubmed ID: 24043886
A Guide to Bioinformatics for Immunologists.
Frontiers in immunology , 2013 | Pubmed ID: 24363654
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved